In this issue:
- Low-risk TAVI trials spark optimism, but surgical societies urge caution over a ‘TAVI-first’ strategy in all risk groups
- Results from the AGENT IDE trial raise hope of the approval of the first drug-coated balloon (DCB) for use in the coronary arteries in the USA
- Statin treatment may benefit patients undergoing surgical aortic valve replacement (SAVR)
- A look ahead to the 2024 Charing Cross (CX) Symposium
- Cardiovascular News speaks to cardiac surgeon and inventor of the soft robotic heart, Jolanda Kluin, about her life and career
